Patients and staff at UW Medical Center participated in the international trial, which has ended. Preliminary findings were published today.
The neutralizing antibody, called S309, is on an accelerated path toward clinical trials
Staff leaves will be temporary; affected employees will maintain benefits, including health insurance
Study findings suggest that women who contract the virus face a higher incidence of a severe pneumonia, which could lead to preterm birth.